الفهرس 
COVEROnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
This prospective study aimed to evaluate the efficacy, safety and tolerability of modified Atkins diet on serum lipid profile (cholesterol, triglyceride, LDL, HDL) in 15 patients diagnosed with symptomatic intractable epilepsy(group A) with age range of 12-36 months ( mean age 27.13+6.63 months) . They were compared to 15 children with symptomatic intractable epilepsy (group B) with age range of 12-36 months (mean age25+6.35months). All the studied patientswere kept on the same doses of their AEDs all through the study. The patients were recruited from Pediatric Neurology outpatient Clinic, Ain Shams University hospital, during the period from November 2010 till May 2011.
All subjects underwent full history taking, and laboratory investigation, including CBC, Na, K and random blood sugar as well as serum lipid profile (cholesterol, triglyceride, LDL, HDL).
Regular outpatient visits were done at monthly intervals for a period of 6 months, during which, any reduction in seizure frequency or severity was recorded for both groups. Regarding patients on MAD, their ketones in urine was carefully monitored. The patient’s toleration to the diet was recorded, and any complication was treated accordingly.
Our study revealed the following:
Most patients reported good or very good tolerance to the modified Atkins diet. Only two patients stopped the diet due to intolerance after 3 months.
As regard the cholesterol serum level, there was significant increase from basal line when compared to both 3 & 6 months levels in group A. Group B showed normal ranges.
Also there was significant increase in LDL serum level from basal line when compared to both 3&6 months levels in group A. Group B showed normal ranges.
Regarding the serum triglyceride and HDL, there were non significant changes on comparing the basal to the 3 &6 months levels.
When we compared group A to group B at 3 and 6 months there was a non significant reduction in seizure frequency at 3 months which became significant at 6 months.
When comparing the seizure frequency in group A at 0, 3, 6 months, our results showed that a significant reduction in frequency of seizure occurred at 6months.
By using Chalfont severity score, our study showed that group A had significantly lower severity of seizure compared to group B. Moreover, seizure severity significantly decreased in group A at 3 and 6 months compared to severity scores upon enrollment.
So from the course of our study we can conclude that; the MAD proved to be a tolerable, safe and effective adjuvant therapy for intractable childhood epilepsy with limited adverse effects changes occurring in the lipid profile of epileptic children on MAD are within acceptable reference range.